Loading...

We've got a brand new version of Simply Wall St! Try it out

Bioethics

OTCPK:BOTH
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BOTH
OTCPK
$4M
Market Cap
  1. Home
  2. US
  3. Diversified Financials
Company description

Bioethics, Ltd. does not have significant operations. The last earnings update was 21 days ago. More info.


Add to Portfolio Compare Print
BOTH Share Price and Events
7 Day Returns
0%
OTCPK:BOTH
-0.8%
US Capital Markets
-1.4%
US Market
1 Year Returns
-
OTCPK:BOTH
15%
US Capital Markets
14.5%
US Market
BOTH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bioethics (BOTH) 0% 0% - - - 475%
US Capital Markets -0.8% 4.1% 6.4% 15% 30.8% 60%
US Market -1.4% 1.3% 4.6% 14.5% 35.7% 48.6%
1 Year Return vs Industry and Market
  • No trading data on BOTH.
  • No trading data on BOTH.

Value

 Is Bioethics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Bioethics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bioethics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Bioethics. This is due to cash flow or dividend data being unavailable. The share price is $0.345.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bioethics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bioethics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:BOTH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.01
OTCPK:BOTH Share Price ** OTCPK (2019-10-02) in USD $0.35
United States of America Capital Markets Industry PE Ratio Median Figure of 82 Publicly-Listed Capital Markets Companies 32.88x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 18.23x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bioethics.

OTCPK:BOTH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:BOTH Share Price ÷ EPS (both in USD)

= 0.35 ÷ -0.01

-47.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bioethics is loss making, we can't compare its value to the US Capital Markets industry average.
  • Bioethics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Bioethics's expected growth come at a high price?
Raw Data
OTCPK:BOTH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -47.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Capital Markets Industry PEG Ratio Median Figure of 37 Publicly-Listed Capital Markets Companies 2.15x
United States of America Market PEG Ratio Median Figure of 2,045 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Bioethics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Bioethics's assets?
Raw Data
OTCPK:BOTH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $-0.03
OTCPK:BOTH Share Price * OTCPK (2019-10-02) in USD $0.35
United States of America Capital Markets Industry PB Ratio Median Figure of 154 Publicly-Listed Capital Markets Companies 6.43x
United States of America Market PB Ratio Median Figure of 5,086 Publicly-Listed Companies 1.77x
OTCPK:BOTH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:BOTH Share Price ÷ Book Value per Share (both in USD)

= 0.35 ÷ -0.03

-11.43x

* Primary Listing of Bioethics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bioethics has negative assets, we can't compare the value of its assets to the US Capital Markets industry average.
X
Value checks
We assess Bioethics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Capital Markets industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Capital Markets industry average (and greater than 0)? (1 check)
  5. Bioethics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Bioethics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioethics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5.2%
Expected Capital Markets industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bioethics expected to grow at an attractive rate?
  • Unable to compare Bioethics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Bioethics's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Bioethics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:BOTH Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Capital Markets Industry Earnings Growth Rate Market Cap Weighted Average 5.2%
United States of America Capital Markets Industry Revenue Growth Rate Market Cap Weighted Average 3.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:BOTH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:BOTH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 0 0
2019-06-30 0 0
2019-03-31 0 0
2018-12-31 0 0
2018-09-30 0 0
2018-06-30 0 0
2018-03-31 0 0
2017-12-31 0 0
2017-09-30 0 0
2017-06-30 0 0
2017-03-31 0 0
2016-12-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Bioethics is high growth as no earnings estimate data is available.
  • Unable to determine if Bioethics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:BOTH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Bioethics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:BOTH Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.01
2019-06-30 -0.01
2019-03-31 -0.01
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Bioethics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Bioethics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Diversified Financials companies here
  2. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Bioethics's filings and announcements here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Bioethics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bioethics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Bioethics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bioethics's growth in the last year to its industry (Capital Markets).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bioethics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Bioethics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Bioethics's 1-year growth to the US Capital Markets industry average as it is not currently profitable.
Earnings and Revenue History
Bioethics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bioethics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:BOTH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 -0.08 0.05
2019-06-30 -0.07 0.05
2019-03-31 -0.08 0.06
2018-12-31 -0.07 0.05
2018-09-30 -0.07 0.06
2018-06-30 -0.08 0.06
2018-03-31 -0.07 0.05
2017-12-31 -0.06 0.05
2017-09-30 -0.06 0.04
2017-06-30 -0.07 0.05
2017-03-31 -0.09 0.05
2016-12-31 -0.12 0.05
2016-09-30 -0.15 0.06
2016-06-30 -0.15 0.05
2016-03-31 -0.12 0.04
2015-12-31 -0.10 0.05
2015-09-30 -0.06 0.03
2015-06-30 -0.02 0.02
2015-03-31 -0.21 0.02
2014-12-31 -0.21 0.02
2014-09-30 -0.21 0.02
2014-06-30 -0.21 0.02
2014-03-31 -0.02 0.02
2013-12-31 -0.02 0.02
2013-09-30 -0.02 0.02
2013-06-30 -0.03 0.02
2013-03-31 -0.03 0.02
2012-12-31 -0.03 0.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Bioethics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Bioethics has efficiently used its assets last year compared to the US Capital Markets industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Bioethics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Bioethics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Capital Markets industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bioethics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Bioethics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bioethics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bioethics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Bioethics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bioethics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Bioethics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bioethics Company Filings, last reported 2 months ago.

OTCPK:BOTH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -0.33 0.29 0.01
2019-06-30 -0.31 0.29 0.02
2019-03-31 -0.29 0.30 0.06
2018-12-31 -0.27 0.25 0.03
2018-09-30 -0.25 0.20 0.00
2018-06-30 -0.24 0.19 0.00
2018-03-31 -0.21 0.19 0.00
2017-12-31 -0.18 0.17 0.00
2017-09-30 -0.17 0.16 0.03
2017-06-30 -0.15 0.16 0.04
2017-03-31 -0.13 0.16 0.05
2016-12-31 -0.12 0.16 0.07
2016-09-30 -0.11 0.16 0.07
2016-06-30 -0.08 0.15 0.04
2016-03-31 -0.04 0.09 0.01
2015-12-31 0.00 0.07 0.02
2015-09-30 0.04 0.04 0.09
2015-06-30 -0.02 0.03 0.00
2015-03-31 -0.02 0.03 0.00
2014-12-31 -0.01 0.03 0.01
2014-09-30 0.00 0.00 0.00
2014-06-30 -0.01 0.00 0.00
2014-03-31 -0.10 0.09 0.00
2013-12-31 -0.10 0.08 0.00
2013-09-30 -0.09 0.08 0.00
2013-06-30 -0.08 0.08 0.01
2013-03-31 -0.08 0.07 0.00
2012-12-31 -0.07 0.07 0.00
  • Bioethics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Bioethics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Bioethics has less than a year of cash runway based on current free cash flow.
  • Bioethics has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.3% each year.
X
Financial health checks
We assess Bioethics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bioethics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Bioethics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Bioethics dividends.
If you bought $2,000 of Bioethics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Bioethics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bioethics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:BOTH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Capital Markets Industry Average Dividend Yield Market Cap Weighted Average of 43 Stocks 1.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1958 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Bioethics has not reported any payouts.
  • Unable to verify if Bioethics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Bioethics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Bioethics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Bioethics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bioethics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bioethics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Bioethics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Scharmann
COMPENSATION $0
AGE 60
TENURE AS CEO 4.4 years
CEO Bio

Mr. Mark A. Scharmann has been the Chief Executive Officer, President, Chief Financial Officer, Treasurer and Secretary of Bioethics Ltd. from July 24, 2015. Mr. Scharmann has been the Chief Executive Officer, President and Secretary of Sears Oil and Gas Corporation since March 25, 2014 and serves as its Treasurer and Chief Financial Officer. He is an Officer of Nevada Land Holding Company. He has been Vice President of Nightingale, Inc. since April 23, 2014. He founded Pacific Alliance, Corp. in 1986 and served as its President and Principal Executive Officer. He is an officer of Roycemore Corporation, a private firm specializing in the development and acquisition of self-storage facilities. Mr. Scharmann is the Founder of Ogden Golf Co. Corporation and served as its President, Principal Accounting Officer and Principal Executive Officer. Mr. Scharmann became interested in investing in emerging growth companies in December 1979 while attending Weber State College. He served as President, Principal Executive Officer, Principal Financial Officer and Treasurer of Immunotechnology Corp. He served as Secretary of Speaking Roses International Inc. Mr. Scharmann is a co-founder of wffl.com and wasatchbasketballleague.com, both youth sports information web sites. He served as Vice President of OTC Communications, Inc. from March 1984 to January 1987. From 1982 to 1996, he served as the President of Royal Oak Resources Corporation. He served as President of Norvex, Inc. He served as Secretary of Millennium Electronics, Inc. He has been a private investor and business consultant since 1980. He compiled and edited a publication titled Digest of Stocks Listed on the Intermountain Stock Exchange (Library of Congress Cat. No. 80-82407). In 1981, he compiled and edited an industry directory called the OTC Penny Stock Digest (Library of Congress Cat. No. 80-82471). In 1981, he compiled and edited an 800 page publication called the OTC Penny Stock Digest. He served as Chairman of Immunotechnology Corp. For the past several years Mr. Scharmann has also consulted with both public and privately held companies relating to management, mergers and acquisitions, debt and equity financing, capital market access, and introductions to investor relations groups. He served as Chairman of the Board of Ogden Golf Co. Corporation. He has been a Director of Sears Oil and Gas Corporation since March 25, 2014 and Nightingale, Inc. since April 23, 2014. He served as Director of Bioethics Ltd. July 24, 2015. He serves as Director of Pacific Alliance, Corp. and Nevada Land Holding Company. He served as a Director of Sagient Research Systems, Inc. until June 11, 2001, Immunotechnology Corp. since February 1997 and Viking Systems, Inc. since December 2, 2003. He served as a Director of Millennium Electronics, Inc., Ogden Golf Co. Corporation and Speaking Roses International Inc. Mr. Scharmann graduated from Weber State University, Ogden, Utah, in 1997, with a Bachelors of Integrated Studies emphasizing Business, Psychology and Health Education.

CEO Compensation
  • Insufficient data for Mark to compare compensation growth.
  • Insufficient data for Mark to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

Mark Scharmann

TITLE
President
AGE
60
TENURE
4.4 yrs
Board of Directors

Mark Scharmann

TITLE
President
AGE
60
TENURE
4.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Bioethics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bioethics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Bioethics, Ltd. does not have significant operations. It intends to seek, investigate, and acquire an interest in a business opportunity. The company was founded in 1990 and is based in Ogden, Utah.

Details
Name: Bioethics, Ltd.
BOTH
Exchange: OTCPK
Founded: 1990
$3,795,000
11,000,000
Website: http://
Address: Bioethics, Ltd.
1661 Lakeview Circle,
Ogden,
Utah, 84403,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK BOTH Common Stock Pink Sheets LLC US USD 20. Apr 1998
Number of employees
Current staff
Staff numbers
0
Bioethics employees.
Industry
Asset Management and Custody Banks
Diversified Financials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/12/05 23:32
End of day share price update: 2019/10/02 00:00
Last earnings filing: 2019/11/14
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.